Autophagy in cancer development, immune evasion, and drug resistance

• Published in: Drug resistance updates 2025-01, Vol.78, p.101170, Article 101170
• Main Authors: Niu, Xuegang, You, Qi, Hou, Kaijian, Tian, Yu, Wei, Penghui, Zhu, Yang, Gao, Bin, Ashrafizadeh, Milad, Aref, Amir Reza, Kalbasi, Alireza, Cañadas, Israel, Sethi, Gautam, Tergaonkar, Vinay, Wang, Lingzhi, Lin, Yuanxiang, Kang, Dezhi, Klionsky, Daniel J.
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Autophagy; Autophagy - drug effects; Autophagy - immunology; Autophagy - physiology; cancer drug resistance; Drug Resistance, Neoplasm - immunology; Humans; Immune Evasion; immunotherapy; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - pathology; Signal Transduction - drug effects; therapeutic approaches; Tumor Escape - drug effects; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; tumor microenvironment remodeling
• ISSN: 1368-7646; 1532-2084; 1532-2084
• DOI: 10.1016/j.drup.2024.101170

Macroautophagy/autophagy is a highly conserved evolutionary mechanism involving lysosomes for the degradation of cytoplasmic components including organelles. The constitutive, basal level of autophagy is fundamental for preserving cellular homeostasis; however, alterations in autophagy can cause disease pathogenesis, including cancer. The role of autophagy in cancer is particularly complicated, since this process acts both as a tumor suppressor in precancerous stages but facilitates tumor progression during carcinogenesis and later stages of cancer progression. This shift between anti-tumor and pro-tumor roles may be influenced by genetic and environmental factors modulating key pathways such as those involving autophagy-related proteins, the PI3K-AKT-MTOR axis, and AMPK, which often show dysregulation in tumors. Autophagy regulates various cellular functions, including metabolism of glucose, glutamine, and lipids, cell proliferation, metastasis, and several types of cell death (apoptosis, ferroptosis, necroptosis and immunogenic cell death). These multifaceted roles demonstrate the potential of autophagy to affect DNA damage repair, cell death pathways, proliferation and survival, which are critical in determining cancer cells’ response to chemotherapy. Therefore, targeting autophagy pathways presents a promising strategy to combat chemoresistance, as one of the major reasons for the failure in cancer patient treatment. Furthermore, autophagy modulates immune evasion and the function of immune cells such as T cells and dendritic cells, influencing the tumor microenvironment and cancer’s biological behavior. However, the therapeutic targeting of autophagy is complex due to its dual role in promoting survival and inducing cell death in cancer cells, highlighting the need for strategies that consider both the beneficial and detrimental effects of autophagy modulation in cancer therapy. Hence, both inducers and inhibitors of autophagy have been introduced for the treatment of cancer. This review emphasizes the intricate interplay between autophagy, tumor biology, and immune responses, offering insights into potential therapeutic approaches that deploy autophagy in the cancer suppression.